

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 November 2009 (12.11.2009)

(10) International Publication Number  
**WO 2009/137776 A1**

(51) International Patent Classification:  
**A61B 5/103 (2006.01) A61F 2/24 (2006.01)**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:  
**PCT/US2009/043312**

(22) International Filing Date:  
**8 May 2009 (08.05.2009)**

(25) Filing Language:  
**English**

(26) Publication Language:  
**English**

(30) Priority Data:  
**61/052,022 9 May 2008 (09.05.2008) US  
12/209,148 11 September 2008 (11.09.2008) US**

(71) Applicant (for all designated States except US): **EDWARDS LIFESCIENCES CORPORATION [US/US]; One Edwards Way, Irvine, CA 92614 (US).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARPENTIER, Alain, F. [FR/FR]; 44 Rue Cortambert, F-75116 Paris (FR). ADAMS, David, H. [US/US]; One Edwards Way, Irvine, CA 92614 (US). ADZICH, Vaso [US/US]; One Edwards Way, Irvine, CA 92614 (US).**


(74) Agents: **YADAV, Rajiv et al.; Edwards Lifesciences LLC, One Edwards Way, Irvine, CA 92614 (US).**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DEGENERATIVE VALVULAR DISEASE SPECIFIC ANNULOPLASTY RINGS



**Fig.24**

(57) Abstract: Annuloplasty rings optimally sized to take into account more of the common degenerative valve pathologies. Each ring has a structural ring body with a shape that complies with predicted shapes of degenerative valvular diseases, such as Fibroelastic deficiency (FED), Marfan's or Barlow's. The predicted shapes are obtained through careful echocardiographic and intraoperative measurements, and often differ for different annulus orifice sizes. For instance, in mitral rings the larger rings have larger minor axis and oblique axis dimensions relative to their major axis dimensions, and are more circular as opposed to D-shaped. The rings may also be three-dimensional and the relative heights around the rings may change for different sized rings. A mitral ring may have a higher anterior saddle relative to a posterior saddle, with the relative heights varying across the ring sizes. The ring may have varying flexibility around the ring periphery which also changes for different ring sizes. A bulge on the sewing cuff forms a step on the outflow side for ease of suturing, which may be indicated by a suture line.

## DEGENERATIVE VALVULAR DISEASE SPECIFIC ANNULOPLASTY RINGS

### Field of the Invention

**[0001]** The present invention relates to medical devices that support and surgically correct a heart valve experiencing valve regurgitation due to degenerative valvular disease. In particular, the present invention pertains to annuloplasty ring prostheses, in a set of rings, the shape of which is specifically adapted to the anatomical configuration of various forms of degenerative mitral valve disease.

### Background of the Invention

**[0002]** The human heart has four valves; the aortic valve, the mitral valve, the pulmonary valve and the tricuspid valve. Various diseases and certain genetic defects of the heart valves can impair their proper functioning. The common defects and diseases affecting each of these valves, and the treatments thereof, are typically different.

**[0003]** As seen in Figures 1 and 2, the mitral valve is a two-leaflet (or bicuspid) structure of connective tissue separating the left atrium (LA) from the left ventricle (LV). The mitral valve functions to maintain blood flow in one direction, i.e., from the atrium toward the ventricle during ventricular relaxation or diastole, while preventing back flow in the opposite direction during ventricular contraction or systole. The bases of the two valve leaflets are attached to a circular fibrous structure of the heart called the annulus (AN), and their free edges to chordae tendinae arising from the papillary muscles of the left ventricle. An anterior leaflet (AL) is relatively large and attaches to the anterior segment of the annulus, while a posterior leaflet (PL) is smaller but extends further circumferentially and attaches to the posterior segment of the annulus. The posterior leaflet presents three scallops identified as P1, P2, P3,

while the corresponding non-scalloped parts of the anterior leaflet are identified as A1, A2, and A3, according to Carpentier's segmentation.

**[0004]** Several diseases can affect the structure and function of the mitral valve. The mitral valve and, less frequently, the tricuspid valve, are prone to deformation and/or dilation of the valve annulus, tearing of the chordae tendineae and leaflet prolapse, which results in valvular insufficiency wherein the valve does not close properly and allows for regurgitation or back flow from the left ventricle into the left atrium. Deformations in the structure or shape of the mitral or tricuspid valve are repairable.

**[0005]** Mitral regurgitation is one of the most common valvular malfunctions in the adult population, and typically involves the elongation or dilation of the posterior two-thirds of the mitral valve annulus, the section corresponding to the posterior leaflet. The most common etiology of systolic mitral regurgitation is myxomatous degeneration, also termed mitral valve prolapse (29% to 70% of cases), which afflicts about 5 to 10 percent of the population in the U.S. Women are affected about twice as often as men. Myxomatous degeneration has been diagnosed as Barlow's syndrome, billowing or ballooning mitral valve, floppy mitral valve, floppy-valve syndrome, prolapsing mitral leaflet syndrome, or systolic click-murmur syndrome. The symptoms include palpitations, chest pain, syncope or dyspnea, and a mid-systolic click (with or without a late systolic murmur of mitral regurgitation). These latter symptoms are typically seen in patients with Barlow's syndrome, where extensive hooding and billowing of both leaflets are the rule. Some forms of mitral valve prolapse seem to be hereditary, though the condition has been associated with Marfan's syndrome, Grave's disease, and other disorders.

**[0006]** Myxomatous degeneration involves weakness in the leaflet structure, leading to thinning of the tissue and loss of coaptation. Barlow's disease is characterized by myxoid degeneration and appears early in life, often before the age of fifty. In Barlow's disease, one or both leaflets of the mitral

valve protrude into the left atrium during the systolic phase of ventricular contraction. The valve leaflets are thick with considerable excess tissue, producing an undulating pattern at the free edges of the leaflets. The chordae are thickened, elongated and may be ruptured. Papillary muscles are occasionally elongated. The annulus is dilated and sometimes calcified. Some of these symptoms are present in other pathologies as well and, therefore, the present application will refer to myxoid degeneration, which is the common pathologic feature of the various diagnoses, including Barlow's syndrome.

[0007] Other causes of mitral regurgitation include ischemic heart disease with ischemic mitral regurgitation (IMR), dilated cardiomyopathy (in which the term "functional mitral regurgitation" [FMR] is used), rheumatic valve disease, mitral annular calcification, infective endocarditis, fibroelastic deficiency (FED), congenital anomalies, endocardial fibrosis, and collagen-vascular disorders. IMR is a specific subset of FMR, but both are usually associated with morphologically normal mitral leaflets. Thus, the types of valve disease that lead to regurgitation are varied and present vastly differently.

[0008] A number of these disease states have been schematically illustrated in Figures 4-8 with Figures 3A and 3B illustrating a normal mitral valve in plan and schematic sectional views across the anterior and posterior leaflets. Figures 4A and 4B show a mitral valve, also in plan and schematic sectional views, where the annulus is dilated and deformed causing mitral regurgitation. Figures 5A and 5B illustrate mitral valves with ruptured and elongated chordae, both causing mitral regurgitation. Figures 6A and 6B show symptoms of Barlow's disease with excess tissue and irregularly thickened leaflets. Barlow's disease is seen most often in the young population and has a long-lasting evolution before the onset of valve regurgitation. Figures 7A and 7B are views of a mitral valve having fibro-elastic deficiency with thinned leaflets and with excess tissue. Fibro-elastic deficiency, first described by Carpentier, is usually seen in more elderly people, and has a short-lasting evolution before valve regurgitation. The anatomical characteristics include a

moderately enlarged kidney-shaped valvular orifice without excess leaflet tissue. The leaflet tissue displays a degeneration of the fibro-elastic bundles. Finally, Figures 8A and 8B illustrate the morphology of a mitral valve in Marfan's disease with excess and thin tissue and elongated chordae. Marfan's is a genetic disorder seen at any age. It has a long-lasting evolution before the onset of regurgitation. The annulus is severely dilated and deformed, the chordae are elongated, and the leaflets are thin and degenerative.

[0009] As is clear from the illustrations of Figures 4-8, many conditions lead to regurgitation. At a structural level, four general types of structural changes of the mitral valve apparatus can cause regurgitation: leaflet retraction from fibrosis and calcification, annular dilation, chordal abnormalities (including rupture, elongation, shortening, or apical tethering or "tenting" as seen in FMR and IMR), and possibly papillary muscle dysfunction.

[0010] Another approach to characterizing mitral valve disease is Carpentier's functional classification of the types of leaflet and chordal motion associated with mitral regurgitation. This is illustrated in Figures 9A-9D, which show anatomical positions during left ventricular systolic contraction when the leaflets of the mitral valve close or coapt. In Type I, Figure 9A, excess dilatation of the annulus (seen in dashed outline) results in lack of coaptation between otherwise normal leaflets. Type II (seen in Figure 9B) mitral regurgitation is due to leaflet prolapse or excessive motion because of rupture or elongation of the chordae tendinae. Type III involves restricted or tethered leaflet motion, classed as occurring during diastole Type IIIa (Figure 9C) or during systole Type IIIb (Figure 9D). Type IIIb (Figure 9C) is typically seen in patients with ischemic mitral regurgitation. The course of the leaflets during the cardiac cycle is represented by the dotted lines. (Derived from Carpentier A: Cardiac valve surgery: the "French correction." J Thorac Cardiovasc Surg 86: 323, 1983.)

[0011] Various surgical techniques may be used to repair diseased or damaged mitral and tricuspid valves. These include but are not limited to

annuloplasty (i.e., contracting the valve annulus to restore the proper size and shape of the valve), quadrangular resection of the leaflets (i.e., removing tissue from enlarged or misshapen leaflets), commissurotomy (i.e., cutting the valve commissures to separate the valve leaflets), shortening and transposition of the chordae tendoneae, reattachment of severed chordae tendoneae or papillary muscle tissue, and decalcification of valve and annulus tissue.

[0012] In patients with degenerative mitral valve disease, valve repair using mitral valvuloplasty valve reconstruction, remodeling, or annuloplasty has been the standard for surgical correction of mitral regurgitation and has provided good long-term results. A rigid support ring (e.g., Carpentier-Edwards Classic® Annuloplasty Ring), a semi-flexible ring (e.g., Carpentier-Edwards Physio® Annuloplasty Ring), or a flexible curved band (e.g., Cosgrove-Edwards® Annuloplasty System) may be used. Closed rings are typically D- or kidney-shaped and generally exhibit a minor/major axis ratio of about 3:4. Some rings are flat or planar, while others exhibit three-dimensional bows. The rings are sutured to the deformed annulus so as to theoretically restore its normal shape and size and restore apposition of the leaflets. It should be noted that not all physicians agree which ring is appropriate for any one condition.

[0013] For illustration of conventional treatment, Figure 10A is a surgeon's or plan view of a mitral valve having a deformed annulus leading to regurgitation. For decades, a suitable method of correcting such a deformed mitral valve annulus was to implant a prosthetic annuloplasty ring to restore normal apposition of the leaflets. Figure 10B shows the annulus after implantation of a Carpentier-Edwards Physio® semi-flexible annuloplasty ring, the most frequently used ring in these cases, although a similar correction can be performed using other rings, such as those described in Figures 12-14. The aim of a conventional annuloplasty ring (and conventional wisdom) is to restore the shape of the normal mitral annulus, or, in some conditions, to overcorrect the shape by pulling inward a segment of the annulus. Unfortunately, the

attachment of an annuloplasty ring sometimes leads to unintended consequences, as explained below

[0014] Despite accepted treatments for correcting mitral regurgitation, there is a need for a simpler and more effective approach that takes into account more of the common pathologies.

#### Summary of the Invention

[0015] Annuloplasty rings designed to restore the specific morphology and dynamic characteristics of heart valves damaged by various degenerative valvular disease to overcome some of the limitations of currently available rings is described. For instance, despite satisfactory results over the years with the currently available Carpentier-Edwards Physio® ring, rings described here better meet the need for treating degenerative valvular diseases.

[0016] The annuloplasty rings will take into account the effects of degenerative valvular diseases over various heart valve sizes and optimize:

- the ring shape and dimensions,
- the saddle shape configuration,
- the ring flexibility,
- the sewing cuff of the ring, and
- the method of ring selection.

[0017] For patients suffering from degenerative valvular diseases, the use of currently available rings to either restore the shape of a normal mitral valve annulus, or overcorrect the annular shape by pulling inward a segment of the annulus yields sub-optimal results. It has been discovered that an optimal technique to correct mitral valve dysfunction in degenerative valvular diseases is to restore the peculiar (abnormal) shape of the annulus characteristic of each type of valvular disease. Furthermore, the ratio between the antero-posterior diameter and the transverse diameter in prior rings is not appropriate for the peculiar ring configuration needed in degenerative valvular disease. Annuloplasty rings are designed taking into account such important

characteristics as the overall shape of the annulus, the dimensions in the different orientations, and the curvature of the different segments of the annulus. The global morphology of the annulus of a heart valve affected by degenerative valvular diseases is assessed by metrology, imaging techniques, and intra-operative measurements. Mathematical models have been used to design optimal shapes and size characteristics of the ring sets.

[0018] A method of implanting an annuloplasty ring described herein therefore includes assessing the characteristic shape of an annulus of a heart valve afflicted by degenerative valvular disease. The “characteristic shape” of such an annulus includes both its size and three-dimensional shape, and may be obtained by direct or indirect measurements of the particular patient, or by a combination of measurements and an understanding of the morphological characteristic of different disease states. The characteristic shape depends, *inter alia*, on the nature of the valvular disease and the valve size. In general, the shape becomes more circular as the ring size increases, and conversely becomes more kidney-shaped as the ring size decreases. For example, a number of disease states have been schematically illustrated in Figures 4-8, representing the most common pathologies of these diseases. The surgeon may also take into account Carpentier’s functional classification of the types of leaflet and chordal motion associated with mitral regurgitation, as illustrated in Figures 9A-9D. Other sources considered authoritative in describing characteristic shapes of diseased mitral annuluses include *A. Carpentier, et al.: J Thorac Cardiovasc Surg* 79: 338, 1980, and *A. Carpentier: Cardiac valve surgery: the “French correction.” J Thorac Cardiovasc Surg* 86: 323, 1983. The surgeon then references the characteristic shape of the annulus of a heart valve for the particular annulus size and degenerative heart valve disease, and selects an annuloplasty ring that corresponds to that annulus size and shape. In other words, rather than trying to constrict the diseased annulus, or otherwise conform the annulus to a “normal” shape, the goal is to fit the ring to the shape of the annulus that is characteristic of the disease that afflicts the valve being treated.

**[0019]** Similarly, it has been discovered that previous annuloplasty rings having a saddle or upward bulge in the anterior sections may not be optimal in the case of degenerative valvular disease. In particular, prior rings can suffer from ring dehiscence at the commissural segments. The saddle shape of ring sets set forth here are, therefore, optimized to conform to specific morphologies and structures of the different degenerative valvular diseases. Again, saddle shape optimization has been obtained from imaging techniques and intra-operative valve analyses. In addition to an increase in the pre-existing upward bow in the anterior section, a posterior bow has been emphasized. The double bow configuration provides a more compliant structure, particularly at the commissures.

**[0020]** A method of implanting an annuloplasty ring at a patient's valve annulus afflicted by a degenerative heart valve disease is disclosed herein. The method includes measuring the size of the valve annulus, and referencing the characteristic shape of the annulus of a heart valve afflicted by the degenerative heart valve disease. An annuloplasty ring is selected having a size and shape that corresponds to the characteristic shape of the degenerative heart valve disease for that annulus size. Finally, the surgeon implants the selected annuloplasty ring at the patient's valve annulus.

**[0021]** In the preceding method, the step of referencing may comprise echocardiographic and intraoperative measurements of the patient's valve annulus. Where the patient's valve annulus is the mitral valve annulus, the measurements typically include transverse diameter, antero-posterior diameter, and at least three oblique dimensions extending from the geometric center of the annulus to the posterior aspect of the annulus. The degenerative heart valve disease may manifest as mitral valve regurgitation.

**[0022]** A method of manufacturing an annuloplasty ring is disclosed herein and comprises first referencing the characteristic shape of the annulus of a heart valve afflicted by a degenerative heart valve disease. Next, an annuloplasty ring is formed with a size and shape that corresponds to the

characteristic shape of the annulus. The characteristic shape may be obtained partly by echocardiographic and intraoperative measurements of an afflicted annulus. For instance, where the patient's valve annulus is the mitral valve annulus, the measurements may include transverse diameter, antero-posterior diameter, and at least three oblique dimensions extending from the geometric center of the annulus to the posterior aspect of the annulus. The degenerative heart valve disease may manifest as mitral valve regurgitation.

**[0023]** The present application also describes a mitral annuloplasty ring for correcting a patient's mitral valve annulus afflicted by a degenerative heart valve disease. The ring has a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments. The ring body has a size and shape that corresponds to the characteristic shape of the heart valve afflicted by the degenerative heart valve disease for that annulus size. The characteristic shape of the annulus of the heart valve afflicted by the degenerative heart valve disease may be obtained partly by echocardiographic and intraoperative measurements of an afflicted annulus. Where the patient's valve annulus is the mitral valve annulus, the measurements may typically include transverse diameter, antero-posterior diameter, and one or more, preferably three, oblique dimensions extending from the central axis of the annulus to the posterior aspect of the annulus. The degenerative heart valve disease may manifest as mitral valve regurgitation.

**[0024]** In the preceding rings and methods of forming, and where the patient's valve annulus is the mitral valve annulus, the ring typically defines a major axis and a minor axis and may be selected to have a size and shape symmetric about the minor axis that preserves or restores full leaflet mobility to the patient's mitral valve. Preferably, the size and shape of the ring as proposed herein addresses the problems of excess tissue and related valve dysfunction commonly seen in degenerative valvular diseases. In one example, for rings having a size of 34 mm or larger, the size and shape of the ring conforms to the abnormal annulus shape of Barlow's disease, rather than a normal shape.

[0025] Where the patient's valve annulus is the mitral valve annulus, the ring typically defines an anterior segment opposite a posterior segment, and two side segments, and may have varying flexibility around its periphery with the posterior segment being more flexible than the anterior segment. In a preferred embodiment, the ring generally defines a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and for rings having a size of 34 mm or larger the D-shape diminishes and becomes generally more circular. In another embodiment, the ring is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1, preferably about 3:1

[0026] The present application also discloses a mitral annuloplasty ring, or method of forming such a ring, comprising a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, wherein the periphery is defined in plan view by four circular arcs, one for each segment, connected at points of tangency. Preferably, the ring defines a horizontal line segment a1-a2 having a length A along the major axis of the ring. Two of the four circular arcs defining the ring body periphery consist of portions of two congruent circles c2, c3 that include points a1 and a2, respectively, and both have a center along line segment a1-a2 and include a point b1 at the center of line segment a1-a2.

[0027] The mitral annuloplasty ring may further define a vertical line segment b1-b2 extending from center point b1 and having a length  $B' = (0.3125 \cdot A)$ , a vertical line segment b1-b3 opposite b1-b2, wherein the line segment b2-b3 defines the minor axis of the ring and has a length B. A third one of the four circular arcs defining the ring body periphery consists of an arc T1-T4 that is tangent at both ends to the outer circles c2 and c3 and includes point b2, and a fourth one of the four circular arcs defining the ring body periphery consists of an arc T2-T3 that is tangent at both ends to the outer circles c2 and c3 and

includes point b3. Desirably, the lengths A and B of the ring body are selected from the groups consisting of:

A is 34 mm, B is about 23.5 mm;  
A is 36 mm, B is about 25.5 mm;  
A is 38 mm, B is about 27.2 mm; and  
A is 40 mm, B is about 28.7 mm.

**[0028]** A mitral annuloplasty ring defined herein has a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments. The ring body in plan view defines a major axis A and a minor axis B extending across from the anterior segment to the posterior segment. The dimensional pairs B and A are selected from the groups consisting of:

A is about 34 mm and B is about 23.5 mm;  
A is about 36 mm and B is about 25.5 mm;  
A is about 38 mm and B is about 27.2 mm; and  
A is about 40 mm and B is about 28.7 mm.

**[0029]** In the aforementioned mitral annuloplasty ring, the ratio of B/A is preferably greater than or equal to 0.69 and less than or equal to 0.73. Furthermore, the axial elevation of the anterior segment is preferably higher than the axial elevation of the posterior segment. In one embodiment, the ring body generally defines a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and as the ring size increases the D-shape diminishes and becomes generally more circular.

**[0030]** Another mitral annuloplasty ring defined herein comprise a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, the ring body in plan view defining a major axis A and a minor axis B extending across from the anterior segment to the posterior segment, wherein A is about 34 mm and B is about 23.5 mm. In a

similar ring, A is about 36 mm and B is about 25.5 mm, or A is about 38 mm and B is about 27.2 mm, or A is about 40 mm and B is about 28.7 mm. Desirably, the ring body is also three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1, preferably about 3:1.

[0031] Another method of manufacturing mitral annuloplasty rings disclosed herein includes forming mitral annuloplasty rings of different sizes where each ring has a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments. Each ring body in plan view defines a major axis dimension A and a minor axis dimension B extending across from the anterior segment to the posterior segment, and each ring has an identified orifice size. The ring bodies in plan view approximate a D-shape for smaller ring sizes and have gradually more circular shapes for larger ring sizes. Desirably, the method includes forming the ring body to be three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1, preferably about 3:1. The shapes of the ring bodies in plan view for different orifice sizes preferably change to comply with predicted shapes of degenerative valvular disease for different annulus orifice sizes. In one example, the ratio B/A for each ring body increases with increasing ring orifice size.

[0032] In accordance with another embodiment, ring sets comprise two upward bows on both the anterior and posterior sections of the ring bodies. Desirably, the anterior bow is more pronounced than the posterior bow so as to adapt to the specific configuration of the mitral annulus. For instance, the anterior section may bow upward between 2-8 mm, preferably between 3-6 mm. In one embodiment, the anterior bow in a set of annuloplasty rings changes across ring sizes to take into account the tendency of the annulus of degenerative valves to flatten as the annulus dilates. The posterior bow

desirably varies between 0.5-4 mm, and preferably between 0.5-2 mm. Again, the relative posterior bow typically flattens for larger annulus sizes.

[0033] The set of annuloplasty rings for correcting a heart valve annulus, comprises a set of rings each having a ring body able to resist deformation when subjected to the stress imparted thereon by the valve annulus. The ring bodies are each arranged around a flow axis having an upward direction and a downward direction, the downward direction corresponding to the direction of blood flow through the valve annulus when the annuloplasty ring is implanted. Each ring has an identified orifice size and the proportional shapes of the ring bodies change with increasing orifice sizes of the rings in the set. The annuloplasty rings may be configured for implantation in various positions, including the mitral and tricuspid positions. The annuloplasty rings are desirably configured for implantation in the mitral position and smaller rings in the set generally define a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and as the orifice sizes of the rings become larger the D-shape diminishes and becomes generally more circular. Furthermore, the ring bodies are preferably three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1. Preferably, the ratio C/D is about 3:1, and the height C of the anterior segment rises up to at least 6 mm above the common datum plane. In a preferred embodiment the change in proportional shapes of the ring bodies is a change in the ratio of the heights C and D of the opposite sides.

[0034] In one particularly useful embodiment, the proportional shapes of the ring bodies change to comply with the characteristic shapes of a particular valvular disease for different annulus orifice sizes. The characteristic shapes of a particular valvular disease may be calculated from echocardiographic and intraoperative measurements. For instance, if the annuloplasty rings are configured for implantation in the mitral position and have an anterior segment opposite a posterior segment, the measurements

include transverse diameter, antero-posterior diameter, and at least three oblique dimensions extending from a central axis of the annulus to the posterior aspect of the annulus.

[0035] In another aspect, a set of mitral annuloplasty rings each comprises a ring body able to resist deformation when subjected to the stress imparted thereon by the mitral valve annulus and arranged around a flow axis having an upward direction and a downward direction. The downward direction corresponds to the direction of blood flow through the mitral valve annulus when the annuloplasty ring is implanted. In accordance with a preferred embodiment, each ring body defines in plan view a major axis A and a minor axis B extending across from an anterior segment to a posterior segment, and each ring has an identified orifice size. In plan view, as seen along the flow axis, the ring bodies in a set of rings defines different proportional shapes depending on the type of degenerative valvular disease in the size of the ring. The proportional shapes of the ring bodies change with increasing orifice sizes of the rings in the set. For instance, the ratio B/A for each ring body increases with increasing orifice sizes of the rings in the set. In the latter case, the ring bodies will have a more pronounced circular shape in the larger sizes and more pronounced kidney or D-shapes in the smaller sizes. The set of rings is optimally sized to take into account more of the common pathologies. The ring bodies may also have varying flexibility around their peripheries, wherein the relative flexibility between the anterior segment and the posterior segment changes with increasing ring orifice size. Desirably, each ring further includes a suture-permeable covering over the ring body, and the covering has a smooth relatively flat inflow side and a stepped outflow side.

[0036] In a still further aspect a set of mitral annuloplasty rings each comprises a ring body able to resist deformation when subjected to the stress imparted thereon by the mitral valve annulus and arranged around a flow axis having an upward direction and a downward direction. The downward direction corresponds to the direction of blood flow through the mitral valve annulus

when the annuloplasty ring is implanted. Each ring has an identified orifice size, and each ring body in plan view defines a major axis A and a minor axis B extending across from an anterior segment to a posterior segment, the ratio B/A for the ring bodies changing with increasing ring orifice size. The ring bodies are preferably D-shaped in plan view with a relatively straight anterior segment opposite a curved posterior segment, wherein the shape of the ring bodies is a more pronounced D-shape for smaller rings and becomes gradually more circular with increasing ring orifice size. The ring bodies may also be three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, and wherein the ratio C/D changes with increasing ring orifice size. Desirably, each ring further includes a suture-permeable covering over the ring body, and the covering has a smooth relatively flat inflow side and a stepped outflow side. The ring bodies each define a continuous or discontinuous periphery.

#### Brief Description of the Drawings

**[0037]** Features and advantages of the devices and methods disclosed herein can be understood with reference to the specification, claims, and appended drawings wherein:

**[0038]** Figure 1 is a cross-sectional view of the left side of the human heart showing the left atrium (LA) separated from the aorta (Ao) by the mitral valve;

**[0039]** Figure 2 is a surgeon's or plan view of a normal mitral valve in the closed position illustrating the anterior leaflet (AL) and the posterior leaflet (PL) attached to the annulus (AN), and indicating eight identifiable leaflet segments;

**[0040]** Figures 3A and 3B illustrate a normal mitral valve in plan and schematic sectional views across the anterior and posterior leaflets;

[0041] Figures 4A and 4B show a mitral valve in plan and schematic sectional views where the annulus is dilated and deformed causing mitral regurgitation;

[0042] Figures 5A and 5B are schematic sectional views of mitral valves with ruptured and elongated chordae, respectively, both causing mitral regurgitation;

[0043] Figures 6A and 6B are plan and schematic sectional views of a mitral valve having symptoms of Barlow's disease with excess tissue and irregularly thickened leaflets;

[0044] Figures 7A and 7B are plan and schematic sectional views of a mitral valve having symptoms of fibro-elastic deficiency with thinned leaflets;

[0045] Figures 8A and 8B are plan and schematic sectional views of a mitral valve having symptoms of Marfan's disease with excess and thin tissue and elongated chordae;

[0046] Figures 9A-9D illustrate Carpentier's functional classification of mitral regurgitation, namely: Type I - normal leaflet motion, though with annular dilatation; Type II - increased leaflet motion (leaflet prolapse); Type IIIa - restricted leaflet motion in systole; and Type IIIb restricted leaflet motion in diastole;

[0047] Figure 10A is a surgeon's or plan view of a mitral valve having a deformed annulus leading to regurgitation;

[0048] Figure 10B shows correction of the deformed mitral valve annulus using a suitable prosthetic annuloplasty ring of the prior art to restore normal apposition of the leaflets;

[0049] Figures 11A-11C are schematic sectional views of a mitral valve corrected with an annuloplasty ring of the prior art as shown in Figure 10B through the diastolic/systolic phases and showing regurgitation resulting from systolic anterior motion (SAM) of the anterior leaflet due to excess tissue;

**[0050]** Figures 12A and 12B are plan and posterior elevational views, respectively, of a Carpentier-Edwards Classic® annuloplasty ring of the prior art;

**[0051]** Figures 13A and 13B are plan and posterior elevational views, respectively, of a Carpentier-Edwards Physio® annuloplasty ring of the prior art;

**[0052]** Figures 14A and 14B are plan and posterior elevational views, respectively, of a Carpentier-McCarthy-Adams IMR ETlogix® annuloplasty ring of the prior art;

**[0053]** Figures 15A-15C are surgeon's views of a mitral valve: 15A) in Barlow's disease displaying excess valvular tissue, 15B) showing an irregular line of leaflet closure and systolic anterior motion (SAM) after correction with a prior art annuloplasty ring, and 15C) after free ends of the prior art annuloplasty ring have been bent outward to restore a desired line of leaflet coaptation;

**[0054]** Figures 16A and 60B are plan and posterior sectional views of an exemplary annuloplasty ring;

**[0055]** Figures 17A/17B, 18A/18B, and 19A/19B show plan and side views of several different sized rings;

**[0056]** Figure 20 is a graph showing the changing minor/major axis proportion of the exemplary ring;

**[0057]** Figures 21A-21C show cutaway plan and sectional views of an exemplary ring;

**[0058]** Figures 22A-22C illustrate the effects of application of opposite inward forces across different oblique planes on the exemplary rings;

**[0059]** Figures 23A-23D illustrate an exemplary sequence of geometric construction of a mitral annuloplasty ring primarily defined by four circular arcs, one for each of the anterior, posterior, and two side segments, and connected at points of tangency;

**[0060]** Figure 24 illustrates a completed exemplary geometric construction of a mitral annuloplasty ring showing primary dimensions;

**[0061]** Figures 25A-25C are several views of an alternative annuloplasty ring having an inner ring body and an outer suture-permeable cover; and

**[0062]** Figure 26 is a plan view of the inner dimension of the ring body of the alternative ring of Figures 25A-25C.

Detailed Description of the Preferred Embodiments

**[0063]** A novel set of annuloplasty rings for correcting pathologies resulting in mitral regurgitation is provided. In one embodiment, a set of rings is structurally defined by ring bodies wherein the proportional shapes of the ring bodies change with increasing identified orifice sizes of the rings in the set. Each ring includes a ring body and an outer covering of suture-permeable material, typically silicone covered with fabric. The set of rings is formed of ring bodies that will initially resist deformation when subjected to the stress imparted thereon by the mitral valve annulus, i.e. the shapes of the ring bodies are formed during manufacture and are not easily manipulated. Examples include ring bodies formed of titanium or Eligiloy® bands. In the absolute sense, however, even these relatively rigid ring bodies can be deformed with the application of sufficient force. However, a ring that is “able to resist deformation” or is “generally rigid” is not a fully flexible ring. Indeed, in a preferred embodiment the rings described herein do not possess the same degree of flexibility in every cross-plane. A desirable configuration consists of a ring that is more flexible across the antero-posterior dimension (the minor axis) than it is in a cross plane transverse to the antero-posterior dimension (the major axis). This preserves the remodeling effect while permitting some flexing in the antero-posterior dimension.

**[0064]** A “set of annuloplasty rings” has a specific meaning of a commercial set of rings that are intentionally manufactured to have differing proportional sizes or shapes. That is, the set of rings would be marketed and/or sold together, and the definition of a set of rings excludes the forcible deformation of an individual ring by a surgeon to change its proportional shape

relative to other rings in that particular commercial set. That would not be a “set” of rings with differing proportions, but instead a set of rings of the same proportion that have been sold and modified after the fact. Also, a “set of annuloplasty rings” excludes the random combination of rings of different sizes from different lines or sets of rings. For instance, a set of Carpentier-Edwards Physio® semi-flexible annuloplasty rings described above are available in sizes 24-40 mm from Edwards Lifesciences of Irvine, CA. Each of these rings has the same size proportions across the commercial set.

**[0065]** Figures 11A-11C are schematic sectional views of a mitral valve corrected with an annuloplasty ring of the prior art, such as a Carpentier-Edwards Physio® semi-flexible annuloplasty ring shown in Figure 10B. Figure 11A shows the diastolic phase in the left ventricle expands to pull blood in through the mitral valve. Figure 11B illustrates the positions of the anterior leaflet (AL) and posterior leaflet (PL) at the initiation of the systolic phase when the left ventricle contracts to force blood through the aortic valve. Because of Systolic Anterior Motion (SAM), and because excess tissue of the posterior leaflet (PL) pushes the anterior leaflet (AL) toward the left ventricular outflow tract, leaflet coaptation is impaired causing residual leakage, or regurgitation. Therefore, the ostensible correction of one mitral condition sometimes creates another problem.

**[0066]** As mentioned above, various annuloplasty rings of the prior art are known for providing the correction to normal mitral annulus shape. For instance, Figures 12A and 12B are plan and posterior elevational views, respectively, of a rigid Carpentier-Edwards Classic® annuloplasty ring. Figures 13A and 13B show a Carpentier-Edwards Physio® semi-rigid annuloplasty ring. The Physio® ring includes a relatively rigid anterior side and a gradually more flexible posterior side, to provide some flexibility to the ring while preserving its annular remodeling effect. Finally, Figures 14A and 14B illustrate a Carpentier-McCarthy-Adams IMR ETlogix® annuloplasty ring, which is relatively rigid around its asymmetric periphery. In all of these and all

known annuloplasty rings, the differently sized rings in a set of marketed rings all have the same size and shape proportions, as well as the same relative flexibilities for those types of rings. The present invention is an improvement on these and other annuloplasty ring designs, including those disclosed in U.S. Patent Nos. 4,055,861 and 5,104,407 both to Lam, Nguyen, and Carpentier, and U.S. Patent Publication No. 2005/0131533 to Carpentier, et al., whose disclosures are expressly incorporated herein.

[0067] In some instances, annuloplasty rings of the prior art can be modified or bent to lessen some of the side-effects described above. Figures 15A-15C are surgeon's views of a mitral valve having symptoms of Barlow's disease treated with an open Carpentier-Edwards Classic® annuloplasty ring. One observed result is systolic anterior motion (SAM), as seen in Figures 15B. The inventor has proposed that in some cases bending the free ends of the annuloplasty ring outwards, as seen in Figure 15C, restores normal apposition of the leaflets. Although this technique is sometimes very effective, it is difficult to predict and requires subjective judgment about how far to bend the ends of the ring. Also, bending the ring may diminish the strength of the device. Furthermore, some rings form continuous peripheries and are not as simple to bend.

[0068] Mitral valves remain competent (non-regurgitant) for a long time despite a severely abnormal valve morphology and structure, including with symptoms of Barlow's disease which creates the most pronounced abnormal valve morphology. Valve regurgitation occurs only when a leaflet dysfunction develops, as categorized by Carpentier in the literature, and as described above with reference to Figures 9A-9D. Also, as mentioned above, attempts to restore the "normal" annulus shape may not improve regurgitation. The inventor has discovered that an efficient valve reconstruction for degenerative valvular diseases involves restoring the peculiar anatomy of the annulus rather than imposing a normal shape thereto. Stated another way, the shapes of the rings in any set of rings conform to the shape of the diseased but well-functioning

valves. A degenerative dysfunction should be corrected by restoring the peculiar configuration of the degenerative valve, and not an anatomically "normal" (or non-diseased) configuration.

**[0069]** The devices described herein, therefore, encompass specifically-shaped rings to conform to abnormal mitral annuluses. The particular shapes of the abnormal annuluses can be obtained from morphometric studies by echocardiography, magnetic resonance imaging (MRI), ultrasound, and direct physical measurements in the operating room. Numerous careful measurements that may be vetted with statistical analysis provide the surgeon with definitions of annulus shape for different degenerative valvular diseases, and for different annulus sizes. Indeed, another aspect recognized by the present inventor is that the annuluses of different sized patients often present differently for the same degenerative valvular disease. The goal in creating specific ring shapes for all the anticipated sizes is to remodel the annulus and restore leaflet co-optation without creating SAM. As explained above, it has been found that, contrary to other diseases, a ring annuloplasty for degenerative valvular disease should restore not the shape of a normal mitral annulus, but the annular shape specific of each type of degenerative valve. One goal of the rings defines herein is to select a mitral annuloplasty ring with a long or major axis and a short or minor axis to have a size and shape symmetric about the minor axis and that preserves or restores full leaflet mobility. The size and shape of the annuloplasty ring desirably addresses the problems of excess tissue and related valve dysfunction commonly seen in degenerative valvular diseases.

**[0070]** In one embodiment, a set of rings of different identified or labeled sizes each having a structural ring body able to resist deformation when subjected to the stress imparted thereon by the mitral valve annulus is contemplated. Each ring body is arranged around a flow axis having an upward direction and a downward direction, the downward direction corresponding to the direction of blood flow through the valve annulus when the annuloplasty ring is implanted. For different orifice sizes, the proportional shapes of the ring

bodies in the set change, depending on the particular degenerative valvular disease at issue. By predicting the shape of the mitral annulus for that disease and that annulus size, a set of rings that will match most patients can therefore be provided. Exemplary ring shapes are shown and described below.

[0071] Figures 16A and 16B are plan and section views of an exemplary annuloplasty ring 70. The ring 70 is shown with a fabric covering 72 over a structural interior support or body 74. Typically a suture-permeable interface 76 fills the space between the covering 72 and interior body 74.

[0072] As seen in Figure 16A, the annuloplasty ring 70 can be described as having a closed or continuous periphery with an anterior (top) section, a posterior (bottom) section and right and left sides therebetween. Preferably, all of the sides are generally curvilinear with no specific demarcations to indicate abrupt transitions therebetween. Rather, smooth transitional sections between the adjacent sides provide curvilinear connections that give the ring a generally rounded (e.g., oval) configuration, or more preferably a somewhat D- or kidney-shaped configuration with a relatively straight anterior segment opposite a curved posterior segment. The kidney-shaped configuration more accurately mimics the mitral annulus. It should be understood, however, that the aspect wherein a set of rings is optimally sized, and more specifically, where the proportional shapes or characteristics of each ring changes with the annulus size, may be beneficial to rings of other shapes and configurations. For instance, changing proportional shapes for different sized rings may be useful for asymmetric rings, three-dimensional rings, discontinuous (C-shaped) rings, tricuspid or ovoid-shaped rings, etc. The devices described herein thus generally provide optimally sized annuloplasty ring sets, though the illustrated application is mitral valve correction.

[0073] The exemplary ring 70 in the plan view of Figure 16A has a minor axis dimension **B** and a major axis dimension **A**, and is three-dimensional. Figure 16B shows preferred heights above a datum plane, with the center of the anterior segment rising to a height **C** and the center of the posterior

segment rising to a height **D**, with a desired ratio of **C/D** >1. The preferred ratio of **C/D** is about 3:1, with the smallest rings rising to a height **C** of about 3 mm on the anterior side and the largest to about 6 mm, potentially up to 8 mm. The height **D** on the posterior side rises to about 2 mm, potentially up to 3 mm.

[0074] Table I below indicates exemplary values of the heights above a datum plane of the anterior segment **C** and the center of the posterior segment **D** of an exemplary ring 70. These magnitudes may vary by  $\pm$  20%, while maintaining the approximate relative sizes across the ring set.

Table I

Labeled ring size (mm)	Anterior Height, <b>C</b> (mm)	Posterior Height, <b>D</b> (mm)
24	3.0	1.0
26	3.3	1.0
28	3.6	1.2
30	4.0	1.2
32	4.4	1.4
34	4.8	1.4
36	5.2	1.6
38	5.6	1.8
40	6.0	2.0

[0075] It should be noted that the ratio of the heights of the opposite sides, anterior and posterior, changes with increasing orifice size. The smallest ring, 24 mm, has a **C/D** ratio of 3.0/1.0, or about 3.0, while a mid-size ring, 34 mm, has a **C/D** ratio of 4.8/1.4, or about 3.4. The **C/D** ratio thus varies as the ring size increases. Although this ratio change may appear slight, the inventors contemplate more significant **C/D** ratio changes for certain degenerative conditions. The trend may be such that the larger rings have a greater or lesser **C/D** ratio than smaller rings, or in other words the anterior height relative to the posterior height becomes greater or lesser in larger rings. Therefore, not only

can the proportional plan view shape of the rings change, but the three-dimensional shape of the rings can also change.

[0076] Two general formulas for anterior and posterior heights are given below for the exemplary ring sets, though those of skill in the art will see that not all rings heights in Table I comport with these formulas. Therefore, they should be viewed as guides only.

$$C = (A - 10) / 5$$

$$D = (C - 2) / 2$$

[0077] The interior body 74 are desirably made of material(s) that are "generally rigid" and will initially resist deformation when subjected to the stress imparted thereon by the mitral valve annulus of an operating human heart. In this sense, "deformation" means substantial permanent deformation from a predetermined or manufactured shape; the opposite concept of which is "elastic" meaning the ability to recover the ring shape in the absence of an external force. A number of "generally rigid" materials can be utilized that will perform this function, including various bio-compatible polymers and metals and/or alloys. Certain polyesters that resist deformation and also rapid degradation within the body may be used (a material that degrades slowly may provide the required initial support). In a preferred embodiment, at least an inner core or body of the annuloplasty ring is made of a suitable metal, such as titanium or its alloys, or ELGILOY made by Elgiloy, L.P. of Elgin, Ill., U.S.A. The core or ring body may be one piece, or may include a plurality of concentric or otherwise cooperating elements.

[0078] The interface 76 is a molded silicone tube or band around the ring body 74 and the fabric covering on the exterior of the ring is desirably Dacron (polyethylene terephthalate). The tubular fabric covering around the silicone sleeve provide an interface for securing the annuloplasty ring to the mitral annulus, although other interfaces are contemplated. For example, rings having outward hooks or barbs are known in the art.

[0079] Typical mitral annuloplasty support rings have a long or major dimension and a short or minor dimension, with the conventional ratio of the minor to major dimension being at most 3:4 (75%), and typically less. The annuloplasty rings described here have a gradually increasing minor axis dimension B to major axis dimension A ratio. The dimensions A and B are measured to the inner edge of the body 74. This increasing dimensional ratio provides rings in the larger sizes that are more suited to correcting conditions where the mitral leaflet is floppy, such as the conditions shown in Figures 2-4, and in general for Type II pathologies seen in Figure 9B. Typically, larger patients exhibit this general condition leading to regurgitation as opposed to smaller patients, for which rings having more conventional B/A ratios are more appropriate.

[0080] Table II below indicates the approximate values of the major and minor axes as measured across the interior of an exemplary ring body 74 (dimensions A and B, respectively, in Figure 16A) for nine different exemplary rings, and also gives the ratios of the minor axis to the major axis. Again, these values may vary by  $\pm$  20%, while maintaining the approximate relative sizes across the ring set. The rings have orifice sizes in even millimeter increments (e.g., 24 mm, 26 mm, etc.) as measured across the major axes. Such rings will have distinct packaging so as to be labeled with the particular size.

Table II

Labeled ring size (mm)	Major axis (mm)	Minor Axis (mm)	B/A ratio
24	24.0	16.5	0.6875
26	26.0	17.7	0.6808
28	28.0	18.9	0.6750
30	30.0	20.4	0.6800
32	32.0	21.9	0.6844
34	34.0	23.5	0.6912
36	36.0	25.5	0.7083

38	38.0	27.2	0.7158
40	40.0	28.7	0.7175

**[0081]** To clarify, an exemplary 40 mm ring will have a major axis dimension A of about 40 mm and a minor axis dimension B of about 28.7 mm. The B/A ratio of the larger rings, such as 34 mm or larger, preferably ranges between 0.69 and 0.73, and the approximation “about” encompasses ring sizes within that ratio range. For instance, a 40 mm ring that has a major axis dimension A of exactly 40 mm, may have a minor axis dimension B of between 27.6 mm ( $0.69 \times 40$ ) and 29.2 mm ( $0.73 \times 40$ ). Further exemplary dimensions will be provided below for sets of rings. Certain curvatures around the ring in plan view are particularly shaped to correct for degenerative valvular diseases.

**[0082]** Figures 17A-19B show plan and side views of several embodiments of different sized rings for comparison. Figures 17A and 17B show a 24 mm ring, Figures 18A and 18B show a 32 mm ring, and Figures 19A and 19B show a 40 mm ring. The overall “look” of the rings are the same though the B/A ratio increases in the larger rings. That is, the larger rings as in Figure 19A are more circular to accommodate valves affected by Barlow’s disease which typically have a greater orifice size. Indeed, Barlow’s, fibroelastic deficiency, and Marfan’s disease all tend to enlarge the orifice of larger annuluses to be more circular. Conversely, the smaller rings as in Figure 17A have a more pronounced D shape to accommodate valves affected by fibroelastic deficiency, which often affects valves of smaller sizes.

**[0083]** From a surgical point of view, whatever the type of degenerative valvular disease, ring selection can be based on measurement of the intercommissural distance and the height of the anterior leaflet. As mentioned above, the particular shapes of the abnormal annuluses can be obtained from morphometric studies by echocardiography, magnetic resonance imaging (MRI), ultrasound, and direct physical measurements in the operating room. The complex morphology of the degenerative mitral valve renders particularly

difficult the selection of the ring. Therefore, in addition to the classic measurements for determining ring size -- the intercommissural dimension and the surface area of the anterior leaflet -- at least two other measurements may be useful: the height of the anterior leaflet (AL) and the height of the three segments P1, P2, P3 of the posterior leaflet (PL). The antero-posterior diameter of the ring should, preferably, be approximately equivalent to the height of the anterior leaflet measured by appropriate sizers.

[0084] Figure 20 is a graph showing the changing minor/major axis proportion of the exemplary ring along line 80 as compared with a line 82 for a prior art ring, the Carpentier-Edwards Physio® ring. This shows the divergence of the ring proportions starting at around the 32 mm ring. Desirably, the B/A ratio increases at least 10% from the smallest ring to the largest ring, and in the exemplary embodiment B/A increases by about 4% (.6875/.7175) from the 24 mm ring to the 40 mm ring.

[0085] Figures 21A-21C show cutaway plan and sectional views showing the construction of an exemplary ring 100. In a preferred embodiment, the annuloplasty ring 100 is defined by a concentric wire band structure 102 resulting in selectively flexibility. Layers are formed by wrapping a single band to form a spiral structure, or by layering individual bands upon one another, with one of such bands shown at 104. Preferably a plurality of individual bands 104 are layered upon one another to form the multi-layered structure 102. The bands 104 are formed from a biocompatible, anti-magnetic material such as Elgiloy®.

[0086] This band structure is held within a fabric sheath 110 in a manner similar to the previously described embodiments. The fabric sheath 110 is a knitted structure with optimal tension to avoid irregularities and wrinkles. Marks are typically placed on the fabric to clearly identify the commissures, and a circular mark provided (e.g., with a green suture) to delineate the enhanced sewing cuff. The longitudinal rigidity of the core, the regular contour and optimal profile of the silicone band together with the extreme thinness and

optimal stretching of the fabric together comprise a unique combination of structural features which minimizes platelet deposit, fibrous proliferation, and thrombus formation.

[0087] Preferably, in order to reduce friction between adjacent bands 104, an elastomeric material such as silicone is placed between the individual band layers, such as seen at 112 in Figure 17. Selective flexibility is provided by movement of the band leaders separated by the silicone material layers therebetween.

[0088] The elastomeric material 112 also surrounds the outside of the band structure 102. As seen in Figures 21B and 21C, the fabric sheath 110 bulges outwards along one side, with this bulge or flange, as seen at 120, filled with the elastomeric material 112. This bulge 120 is preferentially positioned along the outside of the ring 100. Sutures will be passed through the bulge 120 which helps prevent them from catching between the bands 104, or otherwise striking the structural core of the ring. The elastic material 112 desirably comprises a molded silicone band that defines the bulge 120. In Figures 21B and 21C the upper or inflow side 122 is to the left atrium, while the lower or outflow side 124 is toward the ventricle. The inflow side is thus curved, smooth and streamlined to minimize platelet deposits and fibrous proliferation, while the outflow side has a smooth stepped surface to provide a well identified area for placement of sutures used to secure the ring to the annulus. Desirably, a circular green suture line 126 delineating the underside of the enhanced sewing cuff or bulge 112 also maintains tension in the fabric sheath 110, thus eliminating wrinkles and possible thrombus formation and fibrous proliferation. The green suture line 126 acts as an aid to help facilitate implant of the ring by demarking for the surgeon a boundary on the ring within which sutures should not be passed. The line 126 therefore helps prevent the surgeon from snagging the band structure 102 with an implant suture.

[0089] As seen in Figure 21C, the total axial height  $H$  of the exemplary ring 100 is about 3 mm, while the total radial width  $W$  is about 3 mm. With

such a ring 100, the bulge 120 has a height **h** of about 50% of the total height **H**, while the width **w** of the main portion of the ring is about 70% of the total width **W**, meaning the bulge 120 has a width of about 30% of the total width **W**. In the exemplary embodiment, the bulge 120 has an axial height **h** of about 1.5 mm and a radial width of about 0.8 mm.

**[0090]** The radial cross-sectional profile of the rings is preferably reduced as much as possible to minimize turbulence and adverse consequences such as thrombus formation and fibrous proliferation. Consequently, in the embodiment the maximum cross-section of the wire band structure 102 is limited to about 1.5 mm width and 2.5 mm height,  $\pm 10\%$ .

**[0091]** The flexibility of the band structure 102 and thus the ring 100 varies in a direction away from an anterior side. That is, preferably a ratio of the stiffness of the band structure 102, as defined by the bands 104 in the longitudinal direction over the stiffness in the lateral direction is from about 1.15 to about 2.77. In the illustrated embodiment, the band structure 102 includes closely-spaced bands 104 at the anterior side seen in Figure 21B, with less bands that are also spaced apart around the posterior side, as seen in Figure 21C. That is, the anterior side of the ring 100 is substantially straighter and more rigid than the posterior side. One way to increase rigidity of the anterior side is to crimp or spot weld the bands together on that side. Similarly, the actual height of the bands may be greater on the anterior side. Desirably, the axial height of the bands ranges between 1.5-2.5 mm. More detail of similar structure and alternatives thereto can be seen in U.S. Patent No. 5,104,407.

**[0092]** The precise number of band windings forming the body element is dependent upon the materials used for the bands 104, as well as the thickness of the individual band layers forming the multi-layered structure. Generally, from about 1 to about 6 layers or individual bands 104 are used, while the thickness of each layer or band 104 may be from about 0.002 to about 0.008 of an inch.

**[0093]** The use of a layered structure prepared by the overlaying of one or more bands 104 ensures that the force applied against the prosthesis 100 is better distributed over the various layers of the bands. The result is a more even application of load to the entire ring prosthesis 100 in both the longitudinal and lateral directions. Additionally, the layered band structure 102 provides a unique selective flexibility which is predominant in the anterior-posterior (AP) dimension than in the transverse dimension. In other words, the layered band structure 102 has varying degrees of stiffness across different oblique planes as measured by force per unit deflection.

**[0094]** Figures 22A-22C illustrate the effects of application of opposite inward forces across different oblique planes on the exemplary rings. The most deformation, and thus the most flexibility in the ring, is seen in Figure 22A from application of the squeezing force along the antero-posterior plane. The ring is shown in solid line deformed from a dashed outline of the original shape. Figure 22B illustrates the application of the squeezing force in an oblique plane between the major and minor axes. The ring still deforms, but not quite as much. Finally, Figure 22C shows the minimum amount of deformation upon application of opposite inward forces generally along the large dimension or major axis of the ring. Because the anterior side (top side in the figures) is more rigid, it limits the amount of bending of the ring from imposition of such a force. Providing maximum stiffness in the transverse plane (along the major axis) ensures adequate remodeling of the valve annulus.

**[0095]** For large ring sizes, which may be more circular as described above, the selective flexibility may be increased to reduce the stress on the degenerative annulus and, therefore, minimize the incidence of ring dehiscence. Thus, the relative flexibility around each ring across a set of rings may differ. Stated generally, rings across a set of differently-sized rings may differ in their proportional size, shape, or physically characteristics such as flexibility. For example, in smaller rings the posterior side may be more flexible than the anterior side, as in the prior art, but for larger ring sizes in the same set of rings

the posterior flexibility may be even greater relative to the anterior side. The aforementioned structure can be modified to change the flexibility around the ring. More particularly, the axial height of the bands determines their flexibility at any one point, and thus the height of the bands on the posterior side can be less than on the anterior side for greater flexibility on the posterior side. In relative terms, the axial height of the bands on the posterior side of larger rings may be less than the axial height on the anterior side for smaller rings. At the same time, the axially-oriented band structure provides enough transverse rigidity to avoid plication of the ring.

[0096] The stiffness of the rings may be calculated as a gram force (gf) required to deflect the ring 1 mm. One exemplary range of stiffness in the antero-posterior direction is about 44.27-75.33 gf/mm, depending on the size of the ring. A 20% variance on this range is contemplated.

[0097] The rings described herein can be designed using geometric and mathematical formula. Figures 23A-23D and 24 illustrate one exemplary geometric construction of a mitral annuloplasty ring primarily defined by four circular arcs, one for each of the anterior, posterior, and two side segments, and connected at points of tangency.

[0098] First, as seen in Figure 23A, a horizontal line segment a1-a2 is drawn having a length **A** (see Figure 24) of the major axis of the ring being constructed. Therefore, for a 40 mm ring, the length **A** of line segment a1-a2 is 40 mm. The point b1 is located at the center of line segment a1-a2. A vertical line segment b1-b2 is then drawn having a length **B'** (see Figure 24) corresponding to the formula:  $B' = (0.3125 \cdot A) - 0.8$  (all dimensions in mm)

[0099] Still with reference to Figure 23A, congruent triangles b1-b2-a1 and b1-b2-a2 are completed by drawing the hypotenuses along line segments b2-a1 and b2-a2. The point b3 is located by extending the vertical line segment b1-b2 downward so that the length **B** (see Figure 24) of line segment b2-b3 corresponds to the value shown in table II for the corresponding ring size **A**.

[00100] Figure 23B shows a central circle c1 drawn with its center on point b1 and having a radius that extends orthogonally to the two hypotenuses extending along line segments b2-a1 and b2-a2. Another way to look at this is that circle c1 is tangent to both line segments b2-a1 and b2-a2. Next, Figure 23C shows the construction of identical side circles c2 and c3. Side circle c2 includes points a1 and b1, while side circle c3 includes points a2 and b1. The three circles c1, c2, c3 thus divide line segment a1-a2 into four equal segments with at least one half-circle extending along each segment. Another way to state this is that circles c1, c2, c3 are congruent circles whose centers are equidistantly spaced along the major axis line segment a1-a2. Also, the two outer circles c2, c3 include points a1 and a2, respectively, and both including center point b1.

[00101] Now with reference to Figure 23D, large arcs T1-T4 and T2-T3 are drawn across the top and bottom of the geometric form, respectively. Each of these arcs is tangent at both ends to the side circles c2 and c3 and includes, respectively, points b2 and b3. That is, arc T1-T4 is tangent at both ends to the outer circles c2 and c3 and includes point b2, and arc T2-T3 is tangent at both ends to the outer circles c2 and c3 and includes point b3.

[00102] As seen in Figure 24, the geometric shape thus formed provides an outline for the inner dimension of each of the rings in the exemplary set of rings. Specifically, the geometric shape is formed at the sides by arcs T1-T2 and T3-T4 along circles c2 and c3, and at the top and bottom by the large arcs T1-T4 and T2-T3 that are tangent to those circles. The final annuloplasty ring periphery is defined by the four circular arcs T1-T2 and T3-T4, and T1-T4 and T2-T3.

[00103] Figure 24 also illustrates several dimensions r1, r2, r3 from the central point b1 to the posterior side of the ring. Although these dimensions appear as radii, each is not technically a radius but instead an oblique dimension extending from the geometric central point b1 of the ring towards the posterior segment of the ring. Because the arc T2-T3 drawn on the posterior side is not

centered at b1, the dimensions r1, r2, r3 differ. Desirably, the disclosed rings are constructed taking into account a number of measurements of an annulus characteristic of the disease that afflicts the valve being treated, including at least 3, and preferably 5, oblique dimensions extending from the geometric center of the annulus to the posterior aspect of the annulus. Following the ring design methods described herein will result in a ring for each size that has similar if not identical oblique dimensions, as shown at r1, r2, r3 in Figure 24.

[00104] Table III below provides values for some of the dimensions illustrated in figure 24. The major axis dimensions A and B have been listed above in Table II, while the anterior and posterior heights of the exemplary ring were provided in Table I.

Table III

Labeled ring size (mm)	B' (mm)	r1 (mm)	r2 (mm)	r3 (mm)
24	6.7	10.8	10.1	9.8
26	7.3	11.8	10.7	10.4
28	7.9	12.7	11.4	10.9
30	8.6	13.8	12.3	11.8
32	9.2	14.9	13.2	12.7
34	9.8	16.0	14.3	13.7
36	10.4	17.3	15.6	15.1
38	11.1	18.9	17.0	16.1
40	11.7	19.1	17.9	17.5

[00105] Figures 25A-25C are several views of an alternative annuloplasty ring 150 having an inner ring body 152 and an outer suture-permeable cover 154. The inner ring body 152 comprises a series of concentric bands 156, as described above. The cross-section of the ring 150 in Figure 25C is desirably the same as described above, with an inflow side 160 that is curved, smooth and streamlined to minimize platelet deposits and fibrous proliferation, and an

outflow side 162 with a smooth stepped surface to provide a well identified area for placement of sutures used to secure the ring to the annulus.

[00106] Figure 26 is a plan view of an inner band 156 of the ring body 152 of Figures 25A-25C. The concentric bands radiate outward from the inner band, and are generally proportionally congruent. Four different radii  $r_1$ ,  $r_2$ ,  $r_3$ , and  $r_4$  are indicated around the periphery, meaning there are six (6) different circular arc segments around the ring periphery (arcs with radii  $r_2$  and  $r_3$  being on both sides). In contrast to the earlier embodiment, however, some of the radii are centered off the minor axis. In an exemplary embodiment, the inner band 156 is for a 24 mm ring and the dimensions in mm are: A = 24.0, B = 16.6, C = 6.0, D = 5.7, E = 13.6, F = 11.80, G = 1.5,  $r_1$  = 66.04,  $r_2$  = 12.24,  $r_3$  = 5.77 and  $r_4$  = 5.54. The small crosses (x) around the band periphery mark the boundary between arc segments, and the dimensions D, F and G indicate locations of those boundaries.

[00107] Table IV below indicates the approximate values of the major and minor axes (A, B) of the exemplary inner band 156 of the ring body 152 of Figures 25A-25C, as well as exemplary dimensions and curvatures, for nine different exemplary rings. As stated above for other embodiments, these values may vary while maintaining the approximate relative sizes across the ring set. The rings have orifice sizes in even millimeter increments (e.g., 24 mm, 26 mm, etc.) as measured across the major axes.

Table IV

Ring size (mm)	A (mm)	B (mm)	B/A ratio	r <sub>1</sub> (inch)	r <sub>2</sub> (inch)	r <sub>3</sub> (inch)	r <sub>4</sub> (inch)
24	24.0	16.5	0.6875	2.60	0.23	0.22	0.48
26	26.0	17.7	0.6808	2.58	0.25	0.27	0.54
28	28.0	18.9	0.6750	2.55	0.27	0.32	0.61
30	30.0	20.4	0.6800	2.53	0.28	0.37	0.66
32	32.0	21.9	0.6844	2.50	0.30	0.42	0.73
34	34.0	23.5	0.6912	2.40	0.35	0.47	0.79
36	36.0	25.5	0.7083	2.30	0.40	0.49	0.82
38	38.0	27.2	0.7158	2.20	0.45	0.52	1.03
40	40.0	29.2	0.7300	2.10	0.38	0.59	0.83

[00108] While the invention has been described in its preferred embodiments, it is to be understood that the words which have been used are words of description and not of limitation. Therefore, changes may be made within the appended claims without departing from the true scope of the invention.

WHAT IS CLAIMED IS:

1. A method of implanting an annuloplasty ring at a patient's valve annulus afflicted by a degenerative heart valve disease, comprising:

measuring the size of the valve annulus;

referencing the characteristic shape of the annulus of a heart valve afflicted by the degenerative heart valve disease;

selecting an annuloplasty ring having a size and shape that corresponds to the characteristic shape of the degenerative heart valve disease for that annulus size; and

implanting the selected annuloplasty ring at the patient's valve annulus.

2. The method of claim 1, wherein the step of referencing comprises echocardiographic and intraoperative measurements of the patient's valve annulus.

3. The method of claim 2, wherein the patient's valve annulus is the mitral valve annulus, and the measurements include transverse diameter, antero-posterior diameter, and at least three oblique dimensions extending from the geometric center of the annulus to the posterior aspect of the annulus.

4. The method of claim 1, wherein the patient's valve annulus is the mitral valve annulus, and the degenerative heart valve disease manifests as mitral valve regurgitation.

5. The method of claim 1, wherein the patient's valve annulus is the mitral valve annulus, and wherein the ring defines a major axis and a minor axis and is selected to have a size and shape symmetric about the minor axis that preserves or restores full leaflet mobility to the patient's mitral valve.

6. The method of claim 5, wherein the size and shape of the ring addresses the problems of excess tissue and related valve dysfunction commonly seen in degenerative valvular diseases.

7. The method of claim 6, wherein the size and shape of the ring conforms to the annulus shape for Barlow's disease for rings having a size of 34 mm or larger.

8. The method of claim 1, wherein the patient's valve annulus is the mitral valve annulus, and wherein the ring has an anterior segment opposite a posterior segment, and two side segments, and varying flexibility around its periphery with the posterior segment being more flexible than the anterior segment.

9. The method of claim 1, wherein the patient's valve annulus is the mitral valve annulus, and the ring generally defines a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and for rings having a size of 34 mm or larger the D-shape diminishes and becomes generally more circular.

10. The method of claim 1, wherein the patient's valve annulus is the mitral valve annulus, and wherein the ring has an anterior segment opposite a posterior segment, and two side segments, and the ring is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

11. The method of claim 10, wherein the ratio C/D is about 3:1.

12. A method of manufacturing an annuloplasty ring, comprising:  
referencing the characteristic shape of the annulus of a heart  
valve afflicted by a degenerative heart valve disease; and  
forming the annuloplasty ring with a size and shape that  
corresponds to the characteristic shape of the annulus.

13. The method of claim 12, wherein the characteristic shape of the  
annulus of the heart valve afflicted by the degenerative heart valve disease is  
obtained partly by echocardiographic and intraoperative measurements of an  
afflicted annulus.

14. The method of claim 13, wherein the patient's valve annulus is  
the mitral valve annulus, and the measurements include transverse diameter,  
antero-posterior diameter, and at least three oblique dimensions extending from  
the geometric center of the annulus to the posterior aspect of the annulus.

15. The method of claim 12, wherein the patient's valve annulus is  
the mitral valve annulus, and the degenerative heart valve disease manifests as  
mitral valve regurgitation.

16. The method of claim 12, wherein the patient's valve annulus is  
the mitral valve annulus, and wherein the step of forming the ring comprises  
forming the ring to have a major axis and a minor axis and a size and shape  
symmetric about the minor axis that preserves or restores full leaflet mobility to  
the patient's mitral valve.

17. The method of claim 16, wherein the size and shape of the ring  
addresses the problems of excess tissue and related valve dysfunction  
commonly seen in degenerative valvular diseases.

18. The method of claim 17, wherein the size and shape of the ring conforms to the annulus shape for Barlow's disease for rings having a size of 34 mm or larger.

19. The method of claim 12, wherein the patient's valve annulus is the mitral valve annulus, and wherein the step of forming the ring comprises forming an anterior segment opposite a posterior segment, and two side segments, and varying the flexibility around the ring periphery with the posterior segment being more flexible than the anterior segment.

20. The method of claim 12, wherein the patient's valve annulus is the mitral valve annulus, and wherein the step of forming the ring comprises forming generally a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and for rings having a size of 34 mm or larger reducing the prominence of the D-shape such that the ring is more circular.

21. The method of claim 12, wherein the patient's valve annulus is the mitral valve annulus, and wherein the step of forming the ring comprises forming an anterior segment opposite a posterior segment, and two side segments, and forming the ring to be three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

22. The method of claim 21, wherein the ratio C/D is about 3:1.

23. A mitral annuloplasty ring, comprising:

a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, wherein the

periphery is defined in plan view by four circular arcs, one for each segment, connected at points of tangency.

24. The mitral annuloplasty ring of claim 23, wherein the ring defines:

a horizontal line segment a1-a2 having a length A along the major axis of the ring, and

wherein two of the four circular arcs defining the ring body periphery consist of portions of two congruent circles c2, c3 that include points a1 and a2, respectively, and both have a center along line segment a1-a2 and include a point b1 at the center of line segment a1-a2.

25. The mitral annuloplasty ring of claim 24, wherein the ring further defines:

a vertical line segment b1-b2 extending from center point b1 and having a length  $B' = (0.3125 \cdot A)$ ,

a vertical line segment b1-b3 opposite b1-b2, wherein the line segment b2-b3 defines the minor axis of the ring and has a length B;

wherein a third one of the four circular arcs defining the ring body periphery consists of an arc T1-T4 that is tangent at both ends to the outer circles c2 and c3 and includes point b2; and

wherein a fourth one of the four circular arcs defining the ring body periphery consists of an arc T2-T3 that is tangent at both ends to the outer circles c2 and c3 and includes point b3.

26. The mitral annuloplasty ring of claim 25, wherein the lengths A and B of the ring body are selected from the groups consisting of:

A is 34 mm, B is about 23.5 mm;

A is 36 mm, B is about 25.5 mm;

A is 38 mm, B is about 27.2 mm; and

A is 40 mm, B is about 28.7 mm.

27. The mitral annuloplasty ring of claim 23, wherein the ring body further includes varying flexibility around its periphery with the posterior segment being more flexible than the anterior segment.

28. The mitral annuloplasty ring of claim 23, wherein the ring body further includes a three-dimensional periphery with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

29. The mitral annuloplasty ring of claim 28, wherein the ratio C/D is about 3:1.

30. A method of forming a mitral annuloplasty ring, comprising:  
shaping a ring body having a periphery with an anterior segment opposite a posterior segment, and two side segments,  
wherein the periphery is defined in plan view by four circular arcs, one for each segment, connected at points of tangency.

31. The method of claim 30, wherein the step of shaping comprises geometrically constructing the periphery by the steps of:  
drawing a horizontal line segment a1-a2 having a length A of the major axis of the ring being constructed;  
draw two congruent circles c2, c3 including points a1 and a2, respectively, and both including a center point b1 along line a1-a2,  
wherein two of the four circular arcs defining the ring body periphery consist of portions of circles c2 and c3.

32. The method of claim 31, further including the steps of:

drawing a vertical line segment b1-b2 from point b1 and having a length  $B' = (0.3125 \cdot A)$ ,

drawing a vertical line segment b1-b3 opposite b1-b2, wherein the line segment b2-b3 defines the minor axis of the ring being constructed and has a length  $B$ ;

drawing arc T1-T4 tangent at both ends to the outer circles c2 and c3 and including point b2; and

drawing arc T2-T3 tangent at both ends to the outer circles c2 and c3 and including point b3,

wherein the other two of the four circular arcs defining the ring body periphery are arcs T1-T4 and T2-T3.

33. The method of claim 32, wherein the lengths A and B of the ring body are selected from the groups consisting of:

A is 34 mm, B is about 23.5 mm;

A is 36 mm, B is about 25.5 mm;

A is 38 mm, B is about 27.2 mm; and

A is 40 mm, B is about 28.7 mm.

34. The method of claim 30, further including forming the ring body to have varying flexibility around its periphery with the posterior segment being more flexible than the anterior segment.

35. The method of claim 30, wherein the step of shaping further includes shaping the ring body to have a three-dimensional periphery with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

36. The method of claim 35, wherein the ratio C/D is about 3:1.

37. A mitral annuloplasty ring for correcting a patient's mitral valve annulus afflicted by a degenerative heart valve disease, comprising:

a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, the ring body having a size and shape that corresponds to the characteristic shape of the heart valve afflicted by the degenerative heart valve disease for that annulus size.

38. The mitral annuloplasty ring of claim 37, wherein the characteristic shape of the annulus of the heart valve afflicted by the degenerative heart valve disease is obtained partly by echocardiographic and intraoperative measurements of an afflicted annulus.

39. The mitral annuloplasty ring of claim 38, wherein the patient's valve annulus is the mitral valve annulus, and the measurements include transverse diameter, antero-posterior diameter, and at least three oblique dimensions extending from the geometric center of the annulus to the posterior aspect of the annulus.

40. The mitral annuloplasty ring of claim 37, wherein the degenerative heart valve disease manifests as mitral valve regurgitation.

41. The mitral annuloplasty ring of claim 37, wherein the ring body defines a major axis and a minor axis has a size and shape symmetric about the minor axis that preserves or restores full leaflet mobility to the patient's mitral valve.

42. The mitral annuloplasty ring of claim 41, wherein the size and shape of the ring body addresses the problems of excess tissue and related valve dysfunction commonly seen in degenerative valvular diseases.

43. The mitral annuloplasty ring of claim 42, wherein the size and shape of the ring body conforms to the annulus shape for Barlow's disease for rings having a size of 34 mm or larger.

44. The mitral annuloplasty ring of claim 37, wherein the ring body has varying flexibility around its periphery with the posterior segment being more flexible than the anterior segment.

45. The mitral annuloplasty ring of claim 37, wherein the ring body generally defines a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and for rings having a size of 34 mm or larger the D-shape diminishes and becomes generally more circular.

46. The mitral annuloplasty ring of claim 37, wherein the ring body is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

47. The mitral annuloplasty ring of claim 46, wherein the ratio C/D is about 3:1.

48. A mitral annuloplasty ring, comprising:

a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, the ring body in plan view defining a major axis A and a minor axis B extending across from the anterior segment to the posterior segment, the dimensional pairs B and A being selected from the groups consisting of:

A is about 34 mm and B is about 23.5 mm;

A is about 36 mm and B is about 25.5 mm;

A is about 38 mm and B is about 27.2 mm; and  
A is about 40 mm and B is about 28.7 mm.

49. The mitral annuloplasty ring of claim 48, wherein the ratio of B/A is greater than or equal to 0.69 and less than or equal to 0.73.

50. The mitral annuloplasty ring of claim 48, wherein the axial elevation of the anterior segment is higher than the axial elevation of the posterior segment.

51. The mitral annuloplasty ring of claim 50, wherein the ring body is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

52. The mitral annuloplasty ring of claim 51, wherein the ratio C/D is about 3:1.

53. The mitral annuloplasty ring of claim 48, wherein the ring body has varying flexibility around its periphery with the posterior segment being more flexible than the anterior segment.

54. The mitral annuloplasty ring of claim 48, wherein the ring body generally defines a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and wherein as the ring size increases the D-shape diminishes and becomes generally more circular.

55. A mitral annuloplasty ring, comprising:

a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, the ring body in plan view defining a major axis A and a minor axis B extending across

from the anterior segment to the posterior segment, wherein A is about 34 mm and B is about 23.5 mm.

56. The mitral annuloplasty ring of claim 55, wherein the ring body is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

57. The mitral annuloplasty ring of claim 56, wherein the ratio C/D is about 3:1.

58. A mitral annuloplasty ring, comprising:

a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, the ring body in plan view defining a major axis A and a minor axis B extending across from the anterior segment to the posterior segment, wherein A is about 36 mm and B is about 25.5 mm.

59. The mitral annuloplasty ring of claim 58, wherein the ring body is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

60. The mitral annuloplasty ring of claim 59, wherein the ratio C/D is about 3:1.

61. A mitral annuloplasty ring, comprising:

a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, the ring body in plan view defining a major axis A and a minor axis B extending across

from the anterior segment to the posterior segment, wherein A is about 38 mm and B is about 27.2 mm.

62. The mitral annuloplasty ring of claim 61, wherein the ring body is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

63. The mitral annuloplasty ring of claim 62, wherein the ratio C/D is about 3:1.

64. A mitral annuloplasty ring, comprising:

a ring body defining a periphery with an anterior segment opposite a posterior segment, and two side segments, the ring body in plan view defining a major axis A and a minor axis B extending across from the anterior segment to the posterior segment, wherein A is about 40 mm and B is about 28.7 mm.

65. The mitral annuloplasty ring of claim 64, wherein the ring body is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

66. The mitral annuloplasty ring of claim 65, wherein the ratio C/D is about 3:1.

67. A method of manufacturing mitral annuloplasty rings, comprising:

forming mitral annuloplasty rings of different sizes where each ring has a ring body defining a periphery with an anterior segment

opposite a posterior segment, and two side segments, each ring body in plan view defining a major axis dimension A and a minor axis dimension B extending across from the anterior segment to the posterior segment, and each ring having an identified orifice size, wherein the ring bodies in plan view approximating a D-shape for smaller ring sizes and having gradually more circular shapes for larger ring sizes.

68. The method of claim 67, wherein the ring body is three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

69. The method of claim 68, wherein the ratio C/D is about 3:1.

70. The method of claim 67, wherein the shapes of the ring bodies in plan view for different orifice sizes change to comply with predicted shapes of degenerative valvular disease for different annulus orifice sizes.

71. The method of claim 67, wherein the ratio B/A for each ring body increases with increasing ring orifice size.

72. The method of claim 67, wherein the dimensional pairs B and A are selected from the groups consisting of:

A is about 34 mm and B is about 23.5 mm;  
A is about 36 mm and B is about 25.5 mm;  
A is about 38 mm and B is about 27.2 mm; and  
A is about 40 mm and B is about 28.7 mm.

73. A set of annuloplasty rings for correcting a heart valve annulus, comprising:

a set of rings each having a ring body able to resist deformation when subjected to the stress imparted thereon by the valve annulus and arranged around a flow axis having an upward direction and a downward direction, the downward direction corresponding to the direction of blood flow through the valve annulus when the annuloplasty ring is implanted, each ring having an identified orifice size; and

wherein the proportional shapes of the ring bodies change with increasing orifice sizes of the rings in the set.

74. The set of annuloplasty rings of claim 73, wherein the annuloplasty rings are configured for implant in the mitral position and smaller rings in the set generally define a D-shape in plan view with a relatively straight anterior segment opposite a curved posterior segment, and as the orifice sizes of the rings become larger the D-shape diminishes and becomes generally more circular.

75. The set of annuloplasty rings of claim 74, wherein the ring bodies are three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

76. The set of annuloplasty rings of claim 73, wherein the ring bodies are three-dimensional with opposite sides of the ring curving upward above a datum plane, and wherein the change in proportional shapes of the ring bodies is a change in the ratio of the heights of the opposite sides.

77. The set of annuloplasty rings of claim 73, wherein the annuloplasty rings are configured for implant in the mitral position and have an anterior segment opposite a posterior segment, and wherein the ring bodies are three-dimensional with the center of the anterior segment rising to a height C

and the center of the posterior segment rising to height D above a common datum plane, wherein the ratio C/D > 1.

78. The set of annuloplasty rings of claim 77, wherein the ratio C/D is about 3:1.

79. The set of annuloplasty rings of claim 77, wherein the height C of the anterior segment rises up to at least 6 mm above the common datum plane.

80. The set of annuloplasty rings of claim 73, wherein the proportional shapes of the ring bodies change to comply with predicted shapes of a particular valvular disease for different annulus orifice sizes.

81. The set of annuloplasty rings of claim 80, wherein the annuloplasty rings are configured for implant in the mitral position and have an anterior segment opposite a posterior segment, and the valvular disease is Barlow's valve.

82. The set of annuloplasty rings of claim 80, wherein the predicted shapes of a particular valvular disease have been calculated from echocardiographic and intraoperative measurements.

83. The set of annuloplasty rings of claim 82, wherein the annuloplasty rings are configured for implant in the mitral position and have an anterior segment opposite a posterior segment, and wherein the measurements include transverse diameter, antero-posterior diameter, and at least three oblique dimensions extending from the geometric center of the annulus to the posterior aspect of the annulus.

84. The set of annuloplasty rings of claim 73, wherein the annuloplasty rings are configured for implant in the tricuspid position.

85. A set of mitral annuloplasty rings comprising:

a set of rings each having a ring body able to resist deformation when subjected to the stress imparted thereon by the mitral valve annulus and arranged around a flow axis having an upward direction and a downward direction, the downward direction corresponding to the direction of blood flow through the mitral valve annulus when the annuloplasty ring is implanted, each ring body in plan view defining a major axis A and a minor axis B extending across from an anterior segment to a posterior segment, and each ring having an identified orifice size; and

wherein the proportional shapes of the ring bodies change to comply with predicted shapes of degenerative valvular disease for different annulus orifice sizes.

86. The set of mitral annuloplasty rings of claim 85, wherein the plan view shape of the ring bodies is a more pronounced D-shape for smaller ring orifice sizes and becomes gradually more circular as the orifice size increases.

87. The set of mitral annuloplasty rings of claim 85, wherein the ratio B/A for each ring body changes with increasing ring orifice size.

88. The set of mitral annuloplasty rings of claim 85, wherein the ring bodies are three-dimensional with the center of the anterior segment rising to a height C and the center of the posterior segment rising to height D above a common datum plane, and wherein the ratio C/D changes with increasing ring orifice size.

89. The set of mitral annuloplasty rings of claim 85, wherein the ring bodies have varying flexibility around their peripheries, and wherein the relative flexibility between the anterior segment and the posterior segment changes with increasing ring orifice size.

90. The set of mitral annuloplasty rings of claim 85, wherein each ring further includes a suture-permeable covering over the ring body, and the covering has a smooth relatively flat inflow side and a stepped outflow side.

91. A set of mitral annuloplasty rings comprising:

a set of rings each having a ring body able to resist deformation when subjected to the stress imparted thereon by the mitral valve annulus and arranged around a flow axis having an upward direction and a downward direction, the downward direction corresponding to the direction of blood flow through the mitral valve annulus when the annuloplasty ring is implanted, each ring body in plan view defining a major axis A and a minor axis B extending across from an anterior segment to a posterior segment, and each ring having an identified orifice size; and

wherein the ratio B/A for each ring body changes with increasing ring orifice size.

92. The set of mitral annuloplasty rings of claim 91, wherein the ring bodies are generally D-shaped in plan view with a relatively straight anterior segment opposite a curved posterior segment, and wherein the shape of the ring bodies is a more pronounced D-shape for smaller rings and becomes gradually more circular with increasing ring orifice size.

93. The set of mitral annuloplasty rings of claim 91, wherein the ring bodies are three-dimensional with the center of the anterior segment rising to a



height C and the center of the posterior segment rising to height D above a common datum plane, and wherein the ratio C/D changes with increasing ring orifice size.

94. The set of mitral annuloplasty rings of claim 91, wherein each ring further includes a suture-permeable covering over the ring body, and the covering has a smooth relatively flat inflow side and a stepped outflow side.







95. The set of mitral annuloplasty rings of claim 91, wherein the ring bodies each define a continuous periphery.

96. The set of mitral annuloplasty rings of claim 91, wherein the ring bodies each define a discontinuous periphery.







1/15

**Fig. 1****Fig. 2**


2/15

**Fig. 3A****Fig. 3B****Fig. 4A****Fig. 4B****Fig. 5A****Fig. 5B**

3/15


**Fig. 6A****Fig. 6B****Fig. 7A****Fig. 7B****Fig. 8A****Fig. 8B**

4/15




5/15


**Fig. 10A**




**Fig. 10B** (Prior Art)




**Fig. 11A**



**Fig. 11B**




**Fig. 11C**



6/15

**Fig. 12A**


(Prior Art)

**Fig. 12B**


(Prior Art)

**Fig. 13A**


(Prior Art)

**Fig. 13B**

(Prior Art)

**Fig. 14A**

(Prior Art)


**Fig. 14B**

(Prior Art)




7/15


**Fig. 15C**  
(Prior Art)





**Fig. 15B**  
(Prior Art)




**Fig. 15A**




8/15

*Fig. 16B**Fig. 16A*


*Fig. 17A*




*Fig. 18A*




*Fig. 19A*




*Fig. 17B*







*Fig. 18B*




*Fig. 19B*






*Fig.20*



**Fig.21A****Fig.21B****Fig.21C**





12/15





14/15

**Fig.23D****Fig.24**

**Fig.25A****Fig.25B****Fig.26****Fig.25C**

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2009/043312

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61B5/103 A61F2/24

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
A61B A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/65423 A (BAXTER INT [US]) 23 December 1999 (1999-12-23) page 1, line 3 - line 7	12-96
P, X	WO 2008/094469 A (MEDTRONIC INC [US]; RYAN TIMOTHY R [US]; REDMOND JERALD [US]; GLOSS MI) 7 August 2008 (2008-08-07) page 17, line 19 - page 18, line 2	12-96
P, X	WO 2008/098226 A (EDWARDS LIFESCIENCES CORP [US]; CARPENTIER ALAIN [FR]; ADAMS DAVID [US] 14 August 2008 (2008-08-14) the whole document	12-96
P, X	WO 2008/058940 A (MEDTENTIA AB [SE]; KERAENEN OLLI [SE]) 22 May 2008 (2008-05-22) page 16, line 33 - page 17, line 5	12-96
	----- -/-	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

30 July 2009

Date of mailing of the international search report

06/08/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Amaro, Henrique

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/043312

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/034813 A (EDWARDS LIFESCIENCES CORP [US]; ALFIERI OTTAVIO [IT]; CARPENTIER ALAIN) 21 April 2005 (2005-04-21) the whole document -----	23-29, 37-66
X	WO 2005/110290 A (EDWARDS LIFESCIENCES CORP [US]; MCCARTHY PATRICK M [US]) 24 November 2005 (2005-11-24) the whole document -----	23-29, 37-66
X	WO 03/020178 A (EDWARDS LIFESCIENCES CORP [US]) 13 March 2003 (2003-03-13) the whole document -----	23-29, 37-66
X	EP 1 034 753 A (JOSTRA AG [DE] MAQUET CARDIOPULMONARY AG [DE]) 13 September 2000 (2000-09-13) the whole document -----	23-29, 37-66

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US2009/043312**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: **1-11**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Rule 39.1(iv) PCT – Method for treatment of the human or animal body by surgery**
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/US2009/043312

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9965423	A 23-12-1999	AT 277570 T AU 758852 B2 AU 4577399 A CA 2334835 A1 DE 69920694 D1 DE 69920694 T2 EP 1087730 A1 JP 2002518089 T US 6019739 A		15-10-2004 03-04-2003 05-01-2000 23-12-1999 04-11-2004 13-10-2005 04-04-2001 25-06-2002 01-02-2000
WO 2008094469	A 07-08-2008	US 2009036979 A1		05-02-2009
WO 2008098226	A 14-08-2008	US 2009157176 A1 US 2009177276 A1		18-06-2009 09-07-2009
WO 2008058940	A 22-05-2008	AU 2007321262 A1 EP 2081518 A1		22-05-2008 29-07-2009
WO 2005034813	A 21-04-2005	AU 2004279391 A1 BR PI0414870 A CA 2539459 A1 EP 1684670 A2 JP 2007507309 T		21-04-2005 28-11-2006 21-04-2005 02-08-2006 29-03-2007
WO 2005110290	A 24-11-2005	AU 2005244145 A1 BR PI0510249 A CA 2561716 A1 EP 1740126 A1 JP 2007535371 T US 2005246014 A1		24-11-2005 23-10-2007 24-11-2005 10-01-2007 06-12-2007 03-11-2005
WO 03020178	A 13-03-2003	AT 419809 T CA 2456838 A1 EP 1420723 A1 JP 2005501605 T US 2008208331 A1 US 2005043791 A1		15-01-2009 13-03-2003 26-05-2004 20-01-2005 28-08-2008 24-02-2005
EP 1034753	A 13-09-2000	AT 289186 T CN 1269201 A DE 19910233 A1 HK 1031817 A1 JP 2000308652 A		15-03-2005 11-10-2000 21-09-2000 14-10-2005 07-11-2000